Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan 29;74(2):363-364.
doi: 10.1093/cid/ciab468.

Reply to Lapadula et al

Rebecca N Kumar  1 , En-Ling Wu  1 , Valentina Stosor  1   2 , William J Moore  3 , Chad Achenbach  1   4 , Michael G Ison  1   2 , Michael P Angarone  1
Affiliations
Comment

Reply to Lapadula et al

Rebecca N Kumar et al. Clin Infect Dis. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Kumar RN, Wu EL, Stosor V, et al. . Real-world experience of bamlanivimab for COVID-19: a case-control study. Clin Infect Dis 2022; 74:24–31. - PMC - PubMed
    1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506. - PMC - PubMed
    1. Wang D, Hu B, Hu C, et al. . Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323:1061–9. - PMC - PubMed
    1. Chen P, Nirula A, Heller B, et al. ; BLAZE-1 Investigators . SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. N Engl J Med 2021; 384:229–37. - PMC - PubMed
    1. Gottlieb RL, Nirula A, Chen P, et al. . Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 2021; 325:632–44. - PMC - PubMed